Abstract 5107
Background
Brain metastases are currently both common in clinical oncology and a critical problem, since they negatively affect patients' quality of life as well as survival. In the era of targeted therapy, survival for metastatic, recurrent lung cancer has improved. However, improved systemic treatment modalities have led to prolonged disease courses and subsequently to an increased incidence of brain metastases.
Methods
We recruited patients who were diagnosed with non-small cell lung cancer at a Samsung Medical Center from 2008 to 2017. We collected clinical characteristics and treatment pattern by medical chart review and analyzed their mutation status by NGS (ampliseq and cancer scan).
Results
Among 12918 patients who were diagnosed with non-small cell lung cancer and received chemotherapy, 1566 patients received gamma knife surgery and 1209 patients received whole brain radiotherapy. 3922 were EGFR mutant non-small cell lung cancers and received EGFR tyrosine kinase inhibitors (erlotinib: 1424; gefitinib: 2210; afatinib: 606; dacomitinib: 24). Among EGFR-mutant patients, 663 (16.9%) patients received whole brain radiation therap (WBRT) and 765 (19.5%) received gamma-knife surgery. 320 patients who were diagnosed with ALK-positive non-small cell lung cancer received ALK inhibitors (crizotinib: 308; alectinib 54). Among them 51 (15.9%) received WBRT and 81 (25.3%) patients received gamma-knife surgery. 268 patients received gamma-knife surgery three times or more. 51 patients received gamma-knife surgery five times or more (maximum 14 of gamma-knife surgery). Among them, 27 (52.9%) patients were EGFR mutant and 11 (21.6%) patients were ALK-rearrangement non-small cell lung cancer.
Conclusions
In patients with EGFR-mutant or ALK-rearrangement non-small cell lung cancer, local treatment for brain metastasis was performed frequently. A minority of patients have well controlled extracranial disease but poorly controlled intracranial disease, and in these cases strategies to maintain systemic chemotherapy and persistent topical treatments for brain lesions are also helpful. Further research is needed to find out the unique tumor biology of patients with uncontrolled brain metastases.
Clinical trial identification
Legal entity responsible for the study
SMC IRB.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5964 - Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence
Presenter: Karin Birkenkamp-Demtröder
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2197 - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas
Presenter: Evgeny Imyanitov
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2422 - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: independent actors or reciprocal drivers? A translational study by Meet-Uro group
Presenter: Marzia Del Re
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2750 - Validation of a 90-gene assay for tissue origin diagnosis of brain metastases
Presenter: Yulong Zheng
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2960 - Development of a Pan-Cancer Biomarker Panel for Improved Detection of MSI Across all Cancer Types
Presenter: Jeff Bacher
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3791 - bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients
Presenter: Zhenghang Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5189 - Vall d’Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).
Presenter: Cinta Hierro
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5372 - Augmenting TNM Staging with Machine Learning-based Immune Profiling for Improved Prognosis Prediction in Muscle-Invasive Bladder Cancer Patients
Presenter: Nicolas Brieu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2249 - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma
Presenter: Alice Bernard-Tessier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2287 - Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis
Presenter: Marco Iafolla
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract